Computer-Aided Diagnosis in Multiparametric MRI of the Prostate: An Open-Access Online Tool for Lesion Classification with High Accuracy

Identification of impactful imaging biomarker: Clinical applications for breast and prostate carcinoma

BACKGROUND

 Imaging biomarkers are quantitative parameters from imaging modalities, which are collected noninvasively, allow conclusions about physiological and pathophysiological processes, and may consist of single (monoparametric) or multiple parameters (bi- or multiparametric).

METHOD

 This review aims to present the state of the art for the quantification of multimodal and multiparametric imaging biomarkers. Here, the use of biomarkers using artificial intelligence will be addressed and the clinical application of imaging biomarkers in breast and prostate cancers will be explained. For the preparation of the review article, an extensive literature search was performed based on Pubmed, Web of Science and Google Scholar. The results were evaluated and discussed for consistency and generality.

RESULTS AND CONCLUSION

 Different imaging biomarkers (multiparametric) are quantified based on the use of complementary imaging modalities (multimodal) from radiology, nuclear medicine, or hybrid imaging. From these techniques, parameters are determined at the morphological (e. g., size), functional (e. g., vascularization or diffusion), metabolic (e. g., glucose metabolism), or molecular (e. g., expression of prostate specific membrane antigen, PSMA) level. The integration and weighting of imaging biomarkers are increasingly being performed with artificial intelligence, using machine learning algorithms. In this way, the clinical application of imaging biomarkers is increasing, as illustrated by the diagnosis of breast and prostate cancers.

KEY POINTS

· Imaging biomarkers are quantitative parameters to detect physiological and pathophysiological processes.. · Imaging biomarkers from multimodality and multiparametric imaging are integrated using artificial intelligence algorithms.. · Quantitative imaging parameters are a fundamental component of diagnostics for all tumor entities, such as for mammary and prostate carcinomas..

CITATION FORMAT

· Bäuerle T, Dietzel M, Pinker K et al. Identification of impactful imaging biomarker: Clinical applications for breast and prostate carcinoma. Fortschr Röntgenstr 2024; 196: 354 - 362.

Diffusion kurtosis imaging and standard diffusion imaging in the magnetic resonance imaging assessment of prostate cancer

Background and Objective

In recent years, magnetic resonance imaging (MRI) has shown excellent results in the study of the prostate gland. MRI has indeed shown to be advantageous in the prostate cancer (PCa) detection, as in guiding targeting biopsy, improving its diagnostic yield. Although current acquisition protocols provide for multiparametric acquisition, recent evidence has shown that biparametric protocols can be non-inferior in PCa detection. Diffusion-weighted imaging (DWI) sequence, in particular, plays a key role, particularly in the peripheral zone which accounts for the larger part of the prostate. High b-values are generally recommended, although with the possibility of obtaining non-Gaussian diffusion effects, which requires a more sophisticated model for the analysis, namely through the diffusion kurtosis imaging (DKI). Purpose of this narrative review was to analyze the current applications and clinical evidence regarding the use of DKI with a main focus on PCa detection, also in comparison with DWI.

Methods

This narrative review synthesized the findings of literature retrieved from main researches, narrative and systematic reviews, and meta-analyses obtained from PubMed.

Key Content and Findings

DKI analyses the non-Gaussian water diffusivity and describe the effect of signal intensity decay related to high b-value through two main metrics (Dapp and Kapp). Differently from DWI-apparent diffusion coefficient (DWI-ADC) which reflects only water restriction outside of cells, DKI metrics are supposed to represent also the direct interaction of water molecules with cell membranes and intracellular compounds. This review describes current evidence on ADC and DKI metrics in clinical imaging, and finally collect the results derived from the main articles focused on DWI and DKI models in detecting PCa.

Conclusions

DKI advantages, compared to conventional ADC analysis, still remain controversial. Wider application and greater technical knowledge of DKI, however, may help in proving its intrinsic validity in the field of oncology and therefore in the study of clinically significant PCa. Finally, a deep understanding of DKI is important for radiologists to better understand what Kapp and Dapp mean in the context of different cancer and how these metrics may vary specifically in PCa imaging.

The Low Rate of Adherence to Checklist for Artificial Intelligence in Medical Imaging Criteria Among Published Prostate MRI Artificial Intelligence Algorithms

OBJECTIVE

To determine the rigor, generalizability, and reproducibility of published classification and detection artificial intelligence (AI) models for prostate cancer (PCa) on MRI using the Checklist for Artificial Intelligence in Medical Imaging (CLAIM) guidelines, a 42-item checklist that is considered a measure of best practice for presenting and reviewing medical imaging AI research.

MATERIALS AND METHODS

This review searched English literature for studies proposing PCa AI detection and classification models on MRI. Each study was evaluated with the CLAIM checklist. The additional outcomes for which data were sought included measures of AI model performance (eg, area under the curve [AUC], sensitivity, specificity, free-response operating characteristic curves), training and validation and testing group sample size, AI approach, detection versus classification AI, public data set utilization, MRI sequences used, and definition of gold standard for ground truth. The percentage of CLAIM checklist fulfillment was used to stratify studies into quartiles. Wilcoxon's rank-sum test was used for pair-wise comparisons.

RESULTS

In all, 75 studies were identified, and 53 studies qualified for analysis. The original CLAIM items that most studies did not fulfill includes item 12 (77% no): de-identification methods; item 13 (68% no): handling missing data; item 15 (47% no): rationale for choosing ground truth reference standard; item 18 (55% no): measurements of inter- and intrareader variability; item 31 (60% no): inclusion of validated interpretability maps; item 37 (92% no): inclusion of failure analysis to elucidate AI model weaknesses. An AUC score versus percentage CLAIM fulfillment quartile revealed a significant difference of the mean AUC scores between quartile 1 versus quartile 2 (0.78 versus 0.86, P = .034) and quartile 1 versus quartile 4 (0.78 versus 0.89, P = .003) scores. Based on additional information and outcome metrics gathered in this study, additional measures of best practice are defined. These new items include disclosure of public dataset usage, ground truth definition in comparison to other referenced works in the defined task, and sample size power calculation.

CONCLUSION

A large proportion of AI studies do not fulfill key items in CLAIM guidelines within their methods and results sections. The percentage of CLAIM checklist fulfillment is weakly associated with improved AI model performance. Additions or supplementations to CLAIM are recommended to improve publishing standards and aid reviewers in determining study rigor.

Preoperative Evaluation of Gd-EOB-DTPA-Enhanced MRI Radiomics-Based Nomogram in Small Solitary Hepatocellular Carcinoma (≤3 cm) With Microvascular Invasion: A Two-Center Study

BACKGROUND

Preoperative evaluation of microvascular invasion (MVI) in small solitary hepatocellular carcinoma (HCC; maximum lesion diameter ≤ 3 cm) is important for treatment decisions.

PURPOSE

To apply gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI to develop and validate a nomogram for preoperative evaluation of MVI in small solitary HCC and to compare the effectiveness of radiomics evaluation models based on different volumes of interest (VOIs).

STUDY TYPE

Retrospective.

POPULATION

A total of 196 patients include 62 MVI-positive and 134 MVI-negative patients were enrolled (training cohort, n = 105; testing cohort, n = 45; external validation cohort, n = 46).

FIELD STRENGTH/SEQUENCE

3.0 T, fat suppressed fast-spin-echo T2-weighted and Gd-EOB-DTPA-enhanced T1-weighted magnetization-prepared rapid gradient-echo sequences.

ASSESSMENT

Radiomics features were extracted on T2-weighted, arterial phase (AP), and hepatobiliary phase (HBP) images from different VOIs (VOI_intratumor and VOI_{intratumor+peritumor} ) and filtered by the least absolute shrinkage selection operator (LASSO) regression. From VOI_intratumor and VOI_{intratumor+peritumor} , eight radiomics models were constructed based on three MRI sequences (T2-weighted, AP, and HBP) and fused sequences (combined of three sequences). Nomograms were constructed of a clinical-radiological (CR) model and a clinical-radiological-radiomics (CRR) model.

STATISTICAL TESTS

One-way analysis of variance, independent t-test, Chi-square test or Fisher's exact test, Wilcoxon rank-sum test, LASSO, logistic regression analysis, area under the curve (AUC), nomograms, decision curve, net reclassification improvement (NRI), integrated discrimination improvement (IDI) analyses, and DeLong test.

RESULTS

Among eight radiomics models, the fused sequences-based VOI_{intratumor+peritumor} radiomics model showed the best performance. The CRR model containing the best performance radiomics model and CR model with the AUC values were 0.934, 0.889, and 0.875, respectively. NRI and IDI analyses showed that the CRR model improved evaluation efficacy over the CR model for all three cohorts (all P-value <0.05).

DATA CONCLUSION

The CRR model nomogram could preoperatively evaluate MVI in small solitary HCC. The radiomics model based on VOI_{intratumor+peritumor} might achieve better evaluation results.

EVIDENCE LEVEL

4 TECHNICAL EFFICACY STAGE: 2.

Artificial Intelligence Based Algorithms for Prostate Cancer Classification and Detection on Magnetic Resonance Imaging: A Narrative Review

Due to the upfront role of magnetic resonance imaging (MRI) for prostate cancer (PCa) diagnosis, a multitude of artificial intelligence (AI) applications have been suggested to aid in the diagnosis and detection of PCa. In this review, we provide an overview of the current field, including studies between 2018 and February 2021, describing AI algorithms for (1) lesion classification and (2) lesion detection for PCa. Our evaluation of 59 included studies showed that most research has been conducted for the task of PCa lesion classification (66%) followed by PCa lesion detection (34%). Studies showed large heterogeneity in cohort sizes, ranging between 18 to 499 patients (median = 162) combined with different approaches for performance validation. Furthermore, 85% of the studies reported on the stand-alone diagnostic accuracy, whereas 15% demonstrated the impact of AI on diagnostic thinking efficacy, indicating limited proof for the clinical utility of PCa AI applications. In order to introduce AI within the clinical workflow of PCa assessment, robustness and generalizability of AI applications need to be further validated utilizing external validation and clinical workflow experiments.

Clinical value of artificial intelligence in hepatocellular carcinoma: Current status and prospect

Hepatocellular carcinoma (HCC) is the most commonly diagnosed type of liver cancer and the fourth leading cause of cancer-related mortality worldwide. The early identification of HCC and effective treatments for it have been challenging. Due to the sufficient compensatory ability of early patients and its nonspecific symptoms, HCC is more likely to escape diagnosis in the incipient stage, during which patients can achieve a more satisfying overall survival if they undergo resection or liver transplantation. Patients at advanced stages can profit from radical therapies in a limited way. In order to improve the unfavorable prognosis of HCC, diagnostic ability and treatment efficiency must be improved. The past decade has seen rapid advancements in artificial intelligence, underlying its unique usefulness in almost every field, including that of medicine. Herein, we sought and reviewed studies that put emphasis on artificial intelligence and HCC.